Program overview
Context
Indication: Triple-Negative Breast Cancer (TNBC)
Mechanism: Unknown
Modality: Unknown
Sponsor: Fudan University
Watchlist Signal
Ivonescimab Combined With TROP2 ADC
Ivonescimab Combined With TROP2 ADC is flagged as watchlist signal because public records show timeline staleness. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 1/5
Timeline: 2/5
Recruitment burden: 1/5
Results availability: 0/5
Program risk: 2/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT06793332
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT06793332 | Low Signal (RECRUITING) | stale_update_signal | long_recruitment_duration_signal | Low Signal | rare_population_signal |